A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1152 participants.

Also called NCT05929079

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,152 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05929079
Other papers using this trial's data
  • Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial Lancet (London, England), 2026-10-10 DOI, PubMed 42810372

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Argentina, Australia, Brazil, India, Mexico, Romania, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05929079. Randomized; double masking; primary purpose treatment. Start 2023-07-11 (actual); primary completion 2026-06-16 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
Acronym
TRIUMPH-2
Condition
Obesity
Condition
Overweight
Condition
Obstructive Sleep Apnea
Intervention (Drug)
Retatrutide
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct05929079
Content hash
c556c829ecb67a9f68b44ba329a4084e3fe5b742a606f28aa8b5afc320e6f35c